Pinnacle West Capital Stock: Analyst Estimates & Ratings

Pinnacle West Capital (PNW) reported Q2 2026 net income of $178.6M versus $192.6M in Q2 2025, with diluted EPS of $1.43 versus $1.58. Operating revenues rose to $1.46B from $1.36B. Management cited 9.6% weather-normalized sales growth, 9,164 MW peak demand, and a $265B Arizona TSMC investment plan. Full-year EPS guidance is $4.55 to $4.75.

Pinnacle West Capital Corp (PNW) reported Q2 2026 EPS fell $0.15 vs Q2 2025 due to higher interest expense, higher depreciation, and lower transmission revenue from a 2025 true-up. Management discussed IRP filing for end-October, growth near 5% to 7% guidance, and regulatory and capex uncertainty tied to rate cases and projects.

Pinnacle West Capital Corp (PNW) reported Q2 2026 EPS of $1.43, below the Zacks Consensus of $1.49. Revenues rose to $1.46B, above the $1.40B estimate. Operating income was $305.7M. PNW reaffirmed 2026 guidance of $4.55-$4.75 EPS and $5.56-$5.66B revenue.

PINNACLE WEST CAPITAL CORP (PNW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 4, 2026 Media Contact: Analyst Contact: Alan Bunnell (602) 250-3376 Amanda Ho (602) 250-3334 Website: pinnaclewest.com PINNACLE WEST REPORTS LOWER 2026 SECOND-QUARTER FINANCIAL RESULTS COMPARED TO A YEAR AGO • Lower second-quarter financi

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.